Brief Summary
This research study is collecting and storing samples of bone marrow and blood from patients with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma. Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and help predict the recurrence of cancer.
Brief Title
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Detailed Description
OBJECTIVES:
I. Establish a mechanism to bank specimens of tumor cells and host germline DNA from patients with acute lymphoblastic leukemia (ALL) at first and subsequent relapse.
II. Make these specimens available to qualified researchers to study the biology of ALL.
OUTLINE: This is a multicenter study.
Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment.
Patients are followed periodically for up to 10 years.
I. Establish a mechanism to bank specimens of tumor cells and host germline DNA from patients with acute lymphoblastic leukemia (ALL) at first and subsequent relapse.
II. Make these specimens available to qualified researchers to study the biology of ALL.
OUTLINE: This is a multicenter study.
Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment.
Patients are followed periodically for up to 10 years.
Categories
Completion Date
Completion Date Type
Actual
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Non-Hodgkin Lymphoma
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Non-Hodgkin Lymphoma
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of acute lymphoblastic leukemia (ALL) or prior history of non-Hodgkin lymphoma
* In first or subsequent marrow relapse with ≥ 25% blasts in bone marrow and/or peripheral blood
* Bone marrow and/or peripheral blood samples (≥ 5 mL) required at the time of diagnosis of relapse
* No concurrent systemic antileukemic treatment administered for current relapse
* Intrathecal chemotherapy allowed
* On-therapy relapse allowed
* Diagnosis of acute lymphoblastic leukemia (ALL) or prior history of non-Hodgkin lymphoma
* In first or subsequent marrow relapse with ≥ 25% blasts in bone marrow and/or peripheral blood
* Bone marrow and/or peripheral blood samples (≥ 5 mL) required at the time of diagnosis of relapse
* No concurrent systemic antileukemic treatment administered for current relapse
* Intrathecal chemotherapy allowed
* On-therapy relapse allowed
Inclusion Criteria
Inclusion Criteria:
* Diagnosis of acute lymphoblastic leukemia (ALL) or prior history of non-Hodgkin lymphoma
* In first or subsequent marrow relapse with ≥ 25% blasts in bone marrow and/or peripheral blood
* Bone marrow and/or peripheral blood samples (≥ 5 mL) required at the time of diagnosis of relapse
* No concurrent systemic antileukemic treatment administered for current relapse
* Intrathecal chemotherapy allowed
* On-therapy relapse allowed
* Diagnosis of acute lymphoblastic leukemia (ALL) or prior history of non-Hodgkin lymphoma
* In first or subsequent marrow relapse with ≥ 25% blasts in bone marrow and/or peripheral blood
* Bone marrow and/or peripheral blood samples (≥ 5 mL) required at the time of diagnosis of relapse
* No concurrent systemic antileukemic treatment administered for current relapse
* Intrathecal chemotherapy allowed
* On-therapy relapse allowed
Gender
All
Gender Based
false
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Maximum Age
30 Years
NCT Id
NCT00897325
Org Class
Network
Org Full Name
Children's Oncology Group
Org Study Id
AALL05B1
Overall Status
Completed
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Primary Outcomes
Outcome Measure
Banking of tumor cells and germline DNA
Outcome Time Frame
Not Provided
Secondary Ids
Secondary Id
NCI-2009-00310
Secondary Id
COG-AALL05B1
Secondary Id
CDR0000491159
Secondary Id
AALL05B1
Secondary Id
AALL05B1
Secondary Id
U10CA098543
Secondary Id
UG1CA189958
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Study Population
Patient has ALL (or a prior history of Non Hodgkin lymphoma) at first or subsequent marrow relapse with greater than or equal to 25% blasts in the bone marrow and/or peripheral blood.
Std Ages
Child
Adult
Maximum Age Number (converted to Years and rounded down)
30
Minimum Age Number (converted to Years and rounded down)
0
Investigators
Investigator Type
Principal Investigator
Investigator Name
Lisa Gennarini
Investigator Email
lfigueir@montefiore.org
Investigator Phone
Categories Mesh Debug
Blood & Bone Marrow Cancers --- PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA
Blood & Bone Marrow Cancers --- LEUKEMIA, LYMPHOID
Cancer --- LEUKEMIA
Blood & Bone Marrow Cancers --- LEUKEMIA
Cancer --- NEOPLASMS
Blood Disorders --- HEMATOLOGIC DISEASES
Blood & Bone Marrow Cancers --- HEMATOLOGIC DISEASES
Blood & Bone Marrow Cancers --- LYMPHOPROLIFERATIVE DISORDERS
Blood & Bone Marrow Cancers --- LYMPHATIC DISEASES
Blood & Bone Marrow Cancers --- IMMUNOPROLIFERATIVE DISORDERS
Infectious Disease --- IMMUNE SYSTEM DISEASES
Lung --- IMMUNE SYSTEM DISEASES
MeSH Terms
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA
LYMPHOMA, NON-HODGKIN
LEUKEMIA, LYMPHOID
LEUKEMIA
NEOPLASMS BY HISTOLOGIC TYPE
NEOPLASMS
HEMATOLOGIC DISEASES
HEMIC AND LYMPHATIC DISEASES
LYMPHOPROLIFERATIVE DISORDERS
LYMPHATIC DISEASES
IMMUNOPROLIFERATIVE DISORDERS
IMMUNE SYSTEM DISEASES
LYMPHOMA